Neoadjuvant Chemotherapy Deemed New Standard Care in Urothelial Carcinoma

Neoadjuvant gemcitabine-cisplatin produced a “favorable” pathologic response rate in patients with high-grade upper tract urothelial carcinoma.

Related Keywords

New York ,United States ,Memorial Sloan Kettering Cancer Center ,Wesley Yip ,Cancers Symposium ,Cancer Therapy Advisor ,